Specific imaging of immune cell dynamics using novel tracer strategies


Immunotherapies, which harness the immune system to fight disease, are revolutionising the treatment of many cancers and inflammatory diseases. However, while these innovative treatments prove life-saving for some patients, others do not respond to immunotherapies at all, and others experience serious side effects. The Immune-Image project aims to pioneer the use of non-invasive imaging technologies to track the activity of immune cells in the body. Ultimately, the project will make it easier to predict how patients will respond to treatment and monitor their progress during treatment.

To do this, the project will develop tracers capable of highlighting specific immune cells in a range of imaging types, including magnetic resonance imaging (MRI), positron emission tomography (PET), optical imaging (OI) and computed tomography (CT). They will also analyse biopsies and blood samples to build up complete immunological profiles of patients and to correlate imaging findings with pathology; this information will contribute to the development of personalised immunotherapies.


  Show participants on map
EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Imaginab, Inc, Inglewood Ca, United States
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France
  • Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
  • Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain
  • Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio), Barcelona, Spain
  • Stichting Vumc, Amsterdam, Netherlands
  • University of Cambridge, Cambridge, United Kingdom
  • Vib Vzw, Zwijnaarde - Gent, Belgium
  • Vrije Universiteit Brussel, Brussel, Belgium
  • Westfaelische Wilhelms-Universitaet Muenster, Münster, Germany
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Antaros Medical AB, Mölndal, Sweden
  • Lawrencium Legal BV, Amsterdam, Netherlands
  • Stichting Lygature, Utrecht, Netherlands
  • Ttopstart BV, Bilthoven, Netherlands
Patient organisations
  • European Cancer Patient Coalition, Brussels, Belgium
Third parties
  • Cloudselling BV, Rijswijk, Netherlands
  • Universite Paris-Saclay, Saint Aubin, France

NameEU funding in €
Academisch Ziekenhuis Groningen2 174 208
Antaros Medical AB250 000
Commissariat A L Energie Atomique Et Aux Energies Alternatives463 750
Eberhard Karls Universitaet Tuebingen1 103 496
European Cancer Patient Coalition100 000
Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca514 560
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio)433 310
Lawrencium Legal BV400 000
Stichting Lygature450 000
Stichting Vumc4 079 222
Ttopstart BV280 000
University of Cambridge1 041 875
Vib Vzw885 000
Vrije Universiteit Brussel728 329
Westfaelische Wilhelms-Universitaet Muenster1 930 000
Third parties
NameFunding in €
Cloudselling BV120 000
Universite Paris-Saclay46 250
Total Cost15 000 000